Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 366

Results For "THA"

8090 News Found

Health Minister Mandaviya inaugurates 27 greenfield bulk drug park,  13 medical device manufacturing plants
Policy | March 04, 2024

Health Minister Mandaviya inaugurates 27 greenfield bulk drug park, 13 medical device manufacturing plants

PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30


Dr. Mandaviya addresses Governing Council Meeting of the ICMR
News | March 04, 2024

Dr. Mandaviya addresses Governing Council Meeting of the ICMR

ICMR’s budgetary allowance has increased by 4-fold in the past 10 years, showcasing our commitment towards Health Research


Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease
Clinical Trials | March 03, 2024

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg


USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
Drug Approval | March 02, 2024

USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad

This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently


Warren Remedies commences commercial production of oral care products
News | March 02, 2024

Warren Remedies commences commercial production of oral care products

The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra


Cipla incorporates JV company in USA
News | March 02, 2024

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking


Suven announces merger of Cohance Lifesciences
News | March 01, 2024

Suven announces merger of Cohance Lifesciences

The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals


Biocon Biologics secures US market entry date for Bmab 1200
Drug Approval | March 01, 2024

Biocon Biologics secures US market entry date for Bmab 1200

The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA